Category: GeoVax Recent News

Presentation to Highlight Single-Dose MVA and Continuous Cell-Line MVA Manufacturing Innovations ATLANTA, GA – October 06, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that Senthil Ranganathan, PhD, Vice President, Technical Development and CMC Operations, will present at World Vaccine Congress…

CDC Reports Changing U.S. Transmission Dynamics Underscore Importance of Continued Surveillance, Vaccine Preparedness and Resilient MVA Vaccine Supply ATLANTA, GA – September 29, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines against infectious diseases and therapies for solid tumor cancers, today highlighted an important change in the U.S. epidemiology of…

Study Shows Protection Against Highly Pathogenic Clade I Mpox Virus and Durable CD8+ T-Cell Responses Findings Support GeoVax’s Broader Strategy to Expand the Utility of the MVA Vaccine Platform ATLANTA, GA – September 21, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies addressing high-consequence infectious diseases and solid…

BDBV-Specific Construct Developed Using GeoVax Proprietary Rapid Cloning Technology and Builds on Established Filovirus Vaccine Experience GEO-MVA (Mpox/Smallpox Vaccine) Targeted for Phase 3 Initiation Remains Company Priority ATLANTA, GA – September 16, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and solid tumor cancers, today announced…

Independent Evaluation Supports GEO-MVA Pivotal Phase 3 Program Advances GeoVax’s Strategy to Expand and Diversify MVA Vaccine Supply ATLANTA, GA – September 14, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high consequence infectious diseases and solid tumor cancers, today announced that it has entered into a Memorandum…

ATLANTA, GA – September 10, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, today provided an update regarding its Nasdaq listing status and reaffirmed its continued focus on advancing the Company’s key development and strategic priorities. As previously disclosed, GeoVax…

Gavi-funded, ICG-Coordinated Initiative Establishes Long-Term Infrastructure for Timely and Equitable Mpox Vaccine Access During Outbreaks New Stockpile Framework Supports Sustainable Supply and Long-Term Global Preparedness ATLANTA, GA – September 9, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today welcomed the launch of…

ATLANTA, GA – August 26, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of existing warrants (the “Existing Warrants”) to purchase up to 5,697,628 shares of the…

Selections of CRO and European Clinical Sites Represent Significant Milestones Toward Initiation of the GEO-MVA Immunobridging Study ATLANTA, GA – August 25, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and solid tumor cancers, today announced that it has selected the contract research organization (CRO)…

Emerging Evidence of Potential Protection From Authorized Ebola Zaire Vaccine Against Bundibugyo Virus Provides Rationale for Evaluating GeoVax’s MVA-Based Ebola Vaccine Candidates ATLANTA, GA – August 24, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that it has expanded outreach to…

Moderna-Merck Positive Phase 3 Combination Results Reinforce Strategic Rationale for Planned Gedeptin® + KEYTRUDA® Study ATLANTA, GA – August 24, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumors, today highlighted positive Phase 3 results reported by Moderna and Merck evaluating intismeran autogene,…

Former Georgia Life Sciences Chair Selected for CEO Spotlight and Private Global Health Policy Roundtable with U.S. Rep. Rich McCormick ATLANTA, Ga., August 20, 2026 — GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that Chairman, President and Chief Executive Officer David Dodd…